Using quantitative immunohistochemistry in patients at high risk for hepatocellular cancer

Genes and Cancer · Published 2022-06-06 · DOI 10.18632/genesandcancer.220

Authors being retrieved — see the publisher record. https://doi.org/10.18632/genesandcancer.220

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2022

Related articles

• Inactivated FABP5 suppresses malignant progression of prostate cancer cells by inhibiting the activation of nuclear fatty acid receptor PPARγ · Genes and Cancer · 2019 · Same journal
• Multi-kinase targeted therapy as a promising treatment strategy for ovarian tumors expressing sfRon receptor · Genes and Cancer · 2020 · Same journal
• Key drug-targeting genes in pancreatic ductal adenocarcinoma · Genes and Cancer · 2021 · Same journal
• A novel 40kDa N-terminal truncated carboxypeptidase E splice variant: cloning, cDNA sequence analysis and role in regulation of metastatic genes in human cancers · Genes and Cancer · 2019 · Same journal
• Slit2 signaling stimulates Ewing sarcoma growth · Genes and Cancer · 2022 · Same journal
• Pathogenesis to management of hepatocellular carcinoma · Genes and Cancer · 2022 · Same journal
• CEACAMS 1, 5, and 6 in disease and cancer: interactions with pathogens · Genes and Cancer · 2023 · Same journal
• Active Beta-Catenin (ABC) promotes an invasive phenotype in pediatric osteosarcoma · Genes and Cancer · 2026 · Same journal
• A novel t (5; 17) (q35; q21) associated with t (8; 21) (q22; q22) in a patient with acute myeloid leukemia: case report and review of literature · Genes and Cancer · 2023 · Same journal
• Roles of USP1 in Ewing sarcoma · Genes and Cancer · 2024 · Same journal